Dr. Robert G. Gish, Professor of Medicine at Loma Linda University, educates on hepatocellular carcinoma (HCC), early detection, surveillance challenges, and how the HelioLiver test works.
About the webinar
Hepatocellular carcinoma (HCC) is one of the few cancers still rising in incidence, and it is too often found late — when treatment options are narrow. In this webinar, Dr. Robert G. Gish, Professor of Medicine at Loma Linda University and a widely recognized voice in liver disease, lays out why that happens and what earlier detection could change.
Speaking to both clinicians and patients, Dr. Gish makes the case that catching HCC sooner is one of the most powerful levers for improving outcomes — and explains where today’s surveillance falls short of that goal.
What Dr. Gish covers
- The clinical landscape of HCC — who is at risk and why cases are climbing
- Why early detection matters, and how it widens the door to curative treatment
- The real-world challenges of HCC surveillance and where current methods underperform
- How HelioLiver works as a simple, patient-friendly blood test for early detection
Why it matters
Many high-risk patients never receive consistent surveillance, and the tools most often used can miss small, early tumors. A sensitive test that runs from a routine blood draw could make monitoring easier to complete and easier to stick with — helping more cancers be found while they are still most treatable.
View source version on youtube.com.